Skip to content

Released Aug 10, 2023, after the close

10-Q filed Aug 10, 2023, 41 days after period end · 0001390478-23-000019

Q2 2023 · 10-Q
Revenue$0.00— vs Q2 2022no prior Q1 2023 on file
Net Income-$8.84MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.31N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$9,050,000N/M
Operating Cash Flowderived-$7,566,000N/M

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$0.00$0.00$1.90M$0.00
Net Income-$8.84M-$8.41M-$4.61M-$4.43M
EPS Diluted-$0.31-$0.41-$0.30-$0.66

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR